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Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than
cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the
complexity of targeting angiogenesis and the realisation that developing clinically useful antiangiogenic therapy will be more
challenging than originally thought. It is now apparent that new methods and surrogate markers to assess these agents’ biological
activity are crucial for their successful development. This review summarises the currently available clinical data on the development
of surrogate markers of angiogenesis inhibitors.
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Tumour angiogenesis is a complex process modulated by positive
and negative soluble factors released by tumour and host cells and
is essential for neoplastic growth and metastasis (Fidler and Ellis,
1994; Folkman, 1995). Many angiogenic factors, including vascular
endothelial growth factor (VEGF), platelet-derived endothelial cell
growth factor (PDGF), basic fibroblast growth factor (bFGF), and
interleukin-8, have been shown to promote endothelial cell
survival, proliferation, and differentiation. These proangiogenic
factors are essential for capillary morphogenesis during angiogen-
esis (Hanahan and Folkman, 1996; Benjamin and Keshet, 1997).
The microvascular endothelial cell has become an important target
in cancer therapy because tumours recruit endothelial cells early
during angiogenesis (Witte et al, 1998). In addition, endothelial
cells do not develop drug resistance (Boehm et al, 1997; Kerbel,
1997) and are easily accessible through the circulation. Further-
more, an agent that collapses a single capillary may amplify an
antiangiogenic effect within the tumour (Inoue et al, 2000; Ozawa
et al, 2001). These potentially therapeutic benefits of antiangiogen-
esis therapy have led to the development of over 200 anticancer
agents that are in various stages of clinical investigation (at least 45
agents are in clinical trials for the treatment of solid tumours;
www.nci.nih.gov/search/clinicaltrials).
Preclinical studies suggested that angiogenesis inhibitors are
cytostatic (growth-delaying) rather than cytotoxic. Traditionally,
the maximum tolerated dose of a cytotoxic agent (determined by
its dose-limiting toxicity) provided an estimation of the active dose
range for subsequent clinical studies (Simon et al, 1997). However,
for antiangiogenic agents it is uncertain whether doses associated
with clinical toxicity correlate with an antiangiogenic effect. Thus,
because for antiangiogenic agents there is an uncertain relation
between toxicity and response, determining the optimal biological
dose (OBD) of angiogenesis inhibitors depends on a different logic
than conventional cytotoxic chemotherapy. Several clinical studies
have shown that angiogenesis inhibitors are optimal at doses well
below the maximum dose studied (Brewer et al, 2000; Rowinsky
et al, 2000). Clinical investigation of angiogenesis inhibitors has
accentuated the need to develop new biological markers to evaluate
novel agents with putative antiangiogenesis activity.
The complexity of the biology underlying tumour angiogenesis
has generated various approaches to measuring an antiangiogenic
effect (Figure 1). The most commonly used surrogate assays
measure specific serum, plasma, and/or urine levels of angiogenic
factors that are hypothesised to be direct or indirect targets of the
antiangiogenesis agent. Emerging radiologic techniques include
positron emission tomography (PET), magnetic resonance ima-
ging, dynamic computed tomography, and three-dimensional
ultrasound. Each of these techniques is being used to assess
changes in tumour blood flow, vascular permeability and in some
cases metabolism (measured by PET). Other creative surrogate
assays include ex vivo analyses of circulating endothelial precursor
cells (CEPs) that are recruited from the bone marrow during
tumour neovascularisation (Lyden et al, 2001; Reyes et al, 2002).
Perhaps the most direct approach for determining the biological
activity of antiangiogenic therapy involves the analysis of tumour
biopsies before and at specified time points after the administra-
tion of the antiangiogenic agent. Quantifying drug–target inter-
actions at the cellular level (e.g. measuring phosphorylation of
VEGFR-2 following administration of a VEGFR-2 tyrosine kinase
inhibitor) are crucial to determine that the target inhibition has
been achieved for a given angiogenesis inhibitor. Most impor-
tantly, an analysis of tumour biopsies permits the direct
measurement of apoptosis in endothelial cells (an important end
point of antiangiogenic therapy) and the consequences of
endothelial cell death on surrounding tumour cells. Although
these assays are still being developed and the surrogate markers
summarised in this review must be scrupulously validated, we
believe that a combination of such assays can be used to define the
OBDs of angiogenesis inhibitors. Advantages and disadvantages of
these methods are summarised in Table 1. Received 1 April 2003; accepted 23 April 2003
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Proteins thought to be important mediators of angiogenesis can be
measured in serum, plasma, and urine by using enzyme-linked
immunosorbent assays. A significant change in the level of
angiogenic protein(s) after initiation of treatment might provide
an early indication of antiangiogenic activity before clinically
demonstrable reductions in tumour size. Elevated levels of
angiogenic growth factors, proteases, and endothelial adhesion
molecules have been detected in sera of patients with malignant
disease (Dirix et al, 1997). These important promoters of tumour
angiogenesis include VEGF (Takahashi et al, 1994), bFGF
(Fujimoto et al, 1995), urokinase-type plasminogen activator and
its soluble receptor (Xu et al, 1997), E-selectin and vascular cell
adhesion molecule-1 (VCAM-1) (Banks et al, 1993), and von
Willebrand’s factor (vWF) (Gadducci et al, 1994). Of the many
mediators of angiogenesis, VEGF and bFGF are thought to play the
most important roles and thus have been frequently measured as
potential surrogate markers of antiangiogenic activity in many
Phase I/II studies.
In a Phase I dose-escalation study of SU5416, a small-molecule
inhibitor of the VEGF receptor-2 tyrosine kinase, urinary VEGF
and bFGF levels were found to vary 1–2-fold during the course of
therapy but did not correlate with response or treatment dose
(Stopeck et al, 2002). Interestingly, the baseline urine VEGF levels
were significantly lower in the four patients that clinically
responded than in the 18 nonresponders. However, bFGF levels
were not significantly affected. The effects of angiogenesis
inhibitors on the level of angiogenic factors may be drug- or
tumour-type specific and may be dependent on the level of
proteins detectable in different bodily fluids. For example, urine,
serum, and plasma levels of bFGF and VEGF were measured in
patients with renal cell carcinoma enrolled in a Phase II study of
razoxane (Braybrooke et al, 2000), an antiangiogenic topoisome-
rase II inhibitor derived from the chelating agent EDTA. The levels
of urinary VEGF significantly increased in patients who developed
progressive disease but not in those with stable disease. However,
no significant increases were observed in serum VEGF after one
cycle of therapy, although baseline levels of serum VEGF were
significantly higher in patients who subsequently developed
progressive disease than in those with stable disease. Other
mediators of angiogenesis (including serum VCAM-1, vWF, and
urokinase plasminogen activator soluble receptor) hypothesised to
be indirect targets of razoxane were significantly higher in
progressive disease patients than in stable disease patients before
and after one cycle of treatment (Braybrooke et al, 2000). In a
Phase II study of the antiangiogenic agent thalidomide, 16 of 36
patients with recurrent, high-grade gliomas that had radiographic
and clinically stable disease had either stable or decreased serum
bFGF levels (Fine et al, 2000). Interestingly, serum bFGF levels
significantly correlated to survival; patients whose serum bFGF
significantly decreased (compared to baseline) survived approxi-
mately twice as long (43 weeks) than in those patients whose levels
increased beyond the third week of therapy. In our Phase I study of
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Figure 1 Novel assays for measuring surrogate markers of tumour angiogenesis activity. The complex biology of angiogenesis inhibitors has accentuated
the need for developing technologies that can be used to assess the effects of biological markers. A compilation of data from multiple assays including
measuring angiogenic factors in serum, plasma, and urine; tumour biopsy analysis; radiologic imaging; and, recently, ex vivo analyses of isolated peripheral
blood cells (labelled circulating endothelial cells) may facilitate defining the OBD for subsequent clinical studies of angiogenesis inhibitors.
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effects, but their serum VEGF, bFGF, VCAM-1, and E-selectin
levels did not significantly change after treatment (Herbst et al,
2002a).
An important family of proteinases essential for the degradation
of the extracellular matrix (ECM) and the basement membrane
during angiogenesis include the family of matrix metalloprotei-
nases (MMPs) (Liotta and Stetler-Stevenson, 1990). Proteolytic
activation of the MMPs is regulated by the tissue inhibitor
metalloproteinase (TIMP) family of proteins (Gomez et al, 1997).
Matrix metalloproteinases also increase the bioavailability of
factors, such as bFGF that are essential for the ECM (Haro et al,
2000). In patients, high levels of MMP expression have been shown
to correlate directly with metastasis (Liotta and Stetler-Stevenson,
1990; Brown et al, 1993) and poor prognosis (Murray et al, 1996;
Vihinen and Kahari, 2002). Therefore, inhibition of MMPs has
become an important target for antiangiogenesis therapy, and the
proteins themselves have become surrogate markers of antiangio-
genic activity.
Patients enrolled in a Phase I study of MM1270, a nonspecific
inhibitor of MMPs, had a significant increase in serum levels of
MMP-2, MMP-9, TIMP-1, TIMP-2, and bFGF after one cycle of
treatment (Levitt et al, 2001). Importantly, stable disease was
observed in 19 of 92 patients. Other indirect surrogate markers
that were measured but failed to demonstrate any significant
change after treatment included VEGF, VCAM-1, soluble uroki-
nase plasminogen activator receptor, and cathepsin B and H
(proteases involved in the degradation of the ECM). In another
Phase I study, of BAY12-9566, an MMP inhibitor that targets
MMP-2, -3, and -9, only changes in the plasma levels of TIMP-2
were significantly related to dose (Rowinsky et al, 2000). Ironically,
despite achieving biologically relevant plasma concentrations of
BAY12-9566, changes in the levels of MMP-2 and MMP-9 were not
significantly affected by the dose. It is possible that negative
feedback loops become activated, such that increasing inhibition
of the enzyme results in further production. However, in a Phase I
study with COL-3, changes in plasma MMP-2 were significantly
related to dose when compared to patients with progressive disease
vs those with stable disease (Rudek et al, 2001). The direct effect on
MMP-2 is not surprising because COL-3, which was derived from
tetracycline, is a competitive inhibitor of MMP-2 (Seftor et al,
1998). Serum levels of VEGF and bFGF were also measured but
failed to demonstrate any significant correlations.
Other surrogate serum markers include specific target-related
proteins associated with the mechanism(s) of action of the
angiogenesis inhibitor or the disease under study. In a Phase I
study of tetrathiomolybdate (Brewer et al, 2000), an anticopper
agent developed for Wilson’s disease, serum ceruloplasmin was
used as a surrogate marker to monitor total body copper. The goal
of the study was to reduce ceruloplasmin to 20% of baseline value.
Five of six patients with stable disease reached the target range. In
another study, of TNP-470, an analogue of the antibiotic
fumagillin, prostate-specific antigen (PSA) was measured to
monitor antitumour activity in patients with progressive andro-
gen-independent prostate cancer (Logothetis et al, 2001). Surpris-
ingly, a reproducible transient increase in PSA concentrations was
observed in some patients treated and rechallenged with TNP-470;
however, the biological effect on PSA did not appear to be
influenced by dose. Urine bFGF levels measured sequentially
revealed no significant relation to dose or baseline serum bFGF
concentrations.
Thus far, only a few angiogenic factors evaluated in clinical
studies have proven useful for prognosis rather than monitoring
response (Table 2). Validation of factors from homogeneous types
of cancer may facilitate identifying new surrogate markers. Further
studies are needed to refine methods and develop specific
surrogate factors that may be more sensitive to the effects of
angiogenesis inhibitors.
LASER SCANNING CYTOMETRY OF TUMOUR
BIOPSIES
One important approach for evaluating antiangiogenesis activity is
monitoring surrogate markers directly in tumour biopsy speci-
mens. The ability to measure molecular changes (such as
phosphorylation of receptor tyrosine kinases associated with
drug–target interactions before and after therapy) can provide
early proof of whether the biologic agent has successfully reached
its hypothesised target. Some of the most compelling studies
involved quantitative analysis by laser scanning cytometry (LSC)
(Figure 2). Laser scanning cytometry is analogous to fluorescence-
activated cell sorting in that LSC can scan an entire tumour cross-
section, simultaneously interrogating each cell to provide quanti-
tative information such as the percentage of tumour-associated
apoptotic endothelial cells or levels of cellular protein expression.
Laser scanning cytometry-mediated analysis of the effects of
SU5416 and SU6668 in biopsy specimens obtained from Phase I/II
studies demonstrated that these small molecules did not sig-
nificantly inhibit phosphorylation of their primary target, VEGF
receptor-2, or significantly increase apoptosis in tumour-asso-
ciated endothelial cells (Davis et al, in preparation). In contrast,
preclinical studies suggested that these small molecules had great
potential, as they induced significant levels of apoptosis in
endothelial cells, consequently inhibiting tumour growth (Shaheen
et al, 1999). These data may explain the lack of clinical activity
observed in the clinical studies (SU5416 Phase II at University of
Chicago and SU6668 Phase I at MD Anderson Cancer Center), but
most importantly, the results demonstrate that the validity of
VEGF receptor as a therapeutic target has not yet been adequately
tested.
In a Phase I dose-escalation study of endostatin, LSC-mediated
analysis was used to quantify changes in markers of antiangiogenic
activity 56 days after treatment (Herbst et al, 2002b). Changes in
endothelial cell death, microvessel density, and tumour blood flow,
measured by PET (see Radiologic imaging), were all statistically
significant at intermediate doses of the drug (approximately
250mgm
2d) (Davis et al, submitted). In addition, LSC-mediated
analysis of additional surrogate markers hypothesised to be
effected by endostatin including nuclear hypoxia-inducible
Table 1 Comparison of methods used to monitor surrogate markers of antiangiogenic activity
Method Advantages Disadvantages
Angiogenic factors Noninvasive (Urine/serum/plasma) Effects following inhibition of receptor unknown
Quantitative Interpatient variability, tumour specific
PET, MRI, CT, US Assessment of tumour size, blood
flow and volume
Expensive, not routinely available
Determine disease-specific response Effects on tumour blood flow not validated
Biopsy analysis Provides proof of concept Invasive
Quantitative (LSC-based) Effects of tumour heterogeneity unknown
Ex vivo markers Noninvasive, feasible Difficult to detect rare cell populations
Quantitative Requires immediate analysis
Assessing antiangiogenic activity
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of endostatin but failed to reach statistical significance. Impor-
tantly, two patients treated at intermediate doses of endostatin had
minor antitumour responses (Herbst et al, 2002a).
The advantages of LSC-based quantification over standard
manual methods include its automation, its higher sensitivity,
and ability to analyse tens of thousands of cells rather than the
hundreds of cells in a few high-powered microscopic fields. For
example, in another Phase I study of endostatin involving tumour
biopsy specimens, Mundhenke et al (2001) detected apoptosis in
tumour-associated endothelial cells but were not able to discern
clear patterns of cell death and vascular changes, perhaps because
of low analytical power. In addition, surrogate markers in skin
biopsy samples were measured to determine the feasibility of
monitoring antiangiogenic activity. Unfortunately, these markers
failed to demonstrate any significant correlation with endostatin
dose. However, this study did reveal that analysis of skin biopsies
might be useful for monitoring potential toxicity of angiogenesis
inhibitors (Mundhenke et al, 2001). Indeed, the overall lack of
toxicity observed in patients treated with endostatin was consistent
with the analyses of endothelial cell biomarkers in wound sites.
RADIOLOGIC IMAGING
Routine radiographic imaging techniques (magnetic resonance
imaging, dynamic computed tomography, and three-dimensional
ultrasound) are useful for conventional measurement of disease
and evaluating the effect of a biologic agent on tumour size
(Braybrooke et al, 2000; Rudek et al, 2001; Stopeck et al, 2002).
However, changes in tumour size may occur long after initiation of
therapy or in some cases not at all. In addition, the effects of
antiangiogenesis inhibitors on disease stabilisation may be
attributable to continuous, low doses of the drug. Therefore,
developing surrogate markers by employing noninvasive imaging
would facilitate defining the OBD, especially if the antiangiogenic
effects were optimal at intermediate (low) doses or in specific
cancers. For example, three-dimensional ultrasound depicting
vascularity revealed a 4.4-fold decrease in tumour blood flow in a
rib metastasis from renal cell carcinoma after 8 weeks of
tetrathiomolybdate therapy, and dynamic computed tomography
scan imaging confirmed that the lesions with decreased blood flow
were stable (Brewer et al, 2000). In a Phase I study of endostatin,
PET imaging was used to monitor changes in tumour blood flow
[
15O](H2O) and tumour metabolism [
18F](FDG-fluorodeoxyglu-
cose) 28 and 56 days after endostatin therapy (Herbst et al, 2002b).
It was hypothesised that the antiangiogenic effect of endostatin
would decrease tumour blood flow and metabolism. Interestingly,
the study did reveal that endostatin decreased tumour blood flow
having maximal effects between 180 and 300mgm
2d. However,
tumour metabolism appeared to have a complex relation with
tumour blood flow, increasing at a dose of approximately
180mgm
2d before decreasing at doses 4300mgm
2d. Analysis of
the tumour blood flow data using a quadratic polynomial model
showed that endostatin-induced changes in tumour blood flow
were significantly related to dose at 56 days (Davis et al,
submitted). Importantly, the 95% confidence interval identified
for blood flow overlapped the OBD (250mgm
2d) determined from
the tumour biopsy studies. Thus, integration of surrogate marker
data along with imaging studies was crucial for assessing the OBD
of recombinant human endostatin.
EX VIVO MARKERS
The heterogeneity of tumour biology and drug delivery to solid
tumours may lead to variability in the results, making the
interpretation of tumour biopsy and imaging data extremely
challenging. Consequently, other creative strategies are being
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for example, ex vivo analyses of isolated peripheral blood cells. In
one study, a cytokine release assay was used to measure the effect
of MM1270 on release of tumour necrosis factor-a from ex vivo-
stimulated peripheral blood cells (Levitt et al, 2001). Matrix
metalloproteinase inhibitors have been shown to regulate TNF-a
activity (Gearing et al, 1994), and hence, it was hypothesised that
MM1270 treatment would inhibit TNF-a release from stimulated
whole blood cultures. Although there was slight inhibition of TNF-
a release during MM1270 treatment, the results were not
statistically significant, and there was no relation to dose.
Furthermore, attempts to demonstrate apoptosis in endothelial
cells isolated from patients after exposure to angiogenesis
inhibitors, for example, endostatin, failed (Herbst et al, 2002a).
Unfortunately, ex vivo analyses such as these remain complex and
their utility may depend on several factors including the inhibitor’s
relative specificity for tumour-associated endothelial cells, the
sensitivity of the assay to detect effects on rare cell populations,
and limited exposure time of the drug to have an effect on
peripheral blood cells before they are isolated.
The use of flow cytometry to quantify activated circulating
endothelial cells from the peripheral blood of cancer patients has
provided another approach to assessing the effects of antiangio-
genic activity (Mancuso et al, 2001). Recently, work has shown that
VEGF-dependent mobilisation of bone marrow-derived CEPs can
contribute to tumour neovascularisation (Lyden et al, 2001).
Heymach et al and others hypothesised that angiogenesis
inhibitors decrease the number of CEPs (Bertolini et al, 2001)
and increase the number of mature circulating endothelial cells
(CECs) by causing shedding or damage to the endothelium. In a
Phase II study of endostatin, Heymach and colleagues used four-
colour flow cytometry to show that the number of CECs more than
doubled in six of seven patients in the first 2 months of therapy
(personal communication). Importantly, of the six patients with
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disease for at least 6 months. The patient without an increase
developed progressive disease within 6 months. Similar increases
in mature CECs have been observed as early as 6h in four of five
patients treated with ZD6126 (Radema et al, 2002). The feasibility
of measuring markers of early antiangiogenic activity by ex vivo
analyses of endothelial cells is an encouraging approach. However,
further studies are needed to refine the methods and determine
whether these and other surrogate markers correlate with clinical
outcome.
CONCLUSIONS
Although angiogenesis inhibitors have great potential as cancer
therapeutics, the conventional end points of toxicity and response
are inadequate for assessing these agents in clinical studies. The
specificity and cytostatic nature of biologic agents requires the
development of new methods and surrogate markers to identify
doses and schedules with optimal antiangiogenic activity. Under-
standing the novel mechanisms of angiogenesis inhibitors will
facilitate the rational design of surrogate end points.
Although exploratory studies of the use of angiogenic factors in
plasma, serum, and urine as surrogate markers have been
somewhat disappointing, some tumour types may produce higher
levels and more quantifiable factors than other tumours. Thus,
angiogenic factors should continue to be studied, especially in
more homogeneous patient populations. Further, it is anticipated
that the combination of antiangiogenic therapy with traditional
cytotoxic agents will offer optimal therapeutic benefit in the
management of metastatic disease. Paradoxically, the addition of
cytotoxic therapies will introduce toxicities that clinicians hoped to
avoid by using angiogenesis inhibitors. Validation of those
surrogates suggested to be prognostic indicators of clinical
response, for example, urine VEGF, will become critically
important for monitoring chemotherapy combinations employing
cytotoxic and antiangiogenic drugs. Furthermore, preclinical
studies are useful for validating surrogate markers that are
hypothesized to be either indirect or direct targets of the
investigational agent.
Quantitative analysis of drug–target interactions in tumour
biopsies before and after treatment is essential for early proof-of-
concept validation, especially during Phase I/II studies. The effects
of an angiogenesis inhibitor on signal transduction will probably
be evident within hours of exposure to inhibitors of tyrosine
kinase receptors. Thus, confirming drug–target effects, that is, the
presence of apoptotic endothelial cells, in tumour biopsy speci-
mens obtained early (48h) after initiation of therapy may provide
an assessment of optimal antivascular activity. Indeed, LSC-
mediated analysis of apoptosis in tumour cells 48h after initiation
of treatment has proven useful for predicting clinical response to
cytotoxic therapies in breast cancer (Davis et al, 2003). None-
theless, numerous surrogate markers for monitoring antiangio-
genic activity will probably need to be used in clinical studies to
identify an OBD with maximal therapeutic benefit.
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